Guide | From Preconception to the Second Trimester: Genetic Screening and Diagnostic Testing
As technology advances, genetic testing has become an important tool in pregnancy care. Before pregnancy and during the first and second trimesters, it can give prospective parents important information about their baby's health and support informed healthcare decisions. This article introduces genetic testing options at each stage of pregnancy.
Preconception genetic screening: Understanding carrier status
Carrier screening is one of the most common tests before pregnancy. A person who carries a gene for an inherited condition without having symptoms is called a carrier. Carrier screening can determine whether you and your partner carry certain variants and assess the chance of passing them to a child.
Testing can be done before or early in pregnancy, but testing before pregnancy provides more options. Doctors usually use a blood or saliva sample to screen for common inherited conditions, including:
Cystic fibrosis
Fragile X syndrome
Sickle cell anemia
Tay-Sachs disease
Spinal muscular atrophy
Some populations, including non-Hispanic White people, Eastern European Jewish people, and people of African, Mediterranean, or Southeast Asian ancestry, may be more likely to carry certain conditions. Preconception genetic screening may therefore be recommended for higher-risk groups.
First-trimester genetic screening: Assessing the baby's health risks
Early in pregnancy, a doctor may recommend genetic screening for potential health concerns. Common first-trimester options include:
Cell-free fetal DNA testing: This test analyzes fetal DNA in the pregnant woman's blood to screen for Down syndrome, trisomy 18, trisomy 13, and sex chromosome conditions. It can be used from 10 weeks of pregnancy.
Sequential screening: Ultrasound and blood tests are combined to assess the risk of Down syndrome, trisomy 18, and neural tube or brain conditions. It is usually performed between 10 and 13 weeks.
Integrated screening: This combines ultrasound and blood tests to assess the risk of Down syndrome, trisomy 18, and neural tube or brain conditions. The first part is usually performed at 12 weeks and the second during the second trimester. Integrated screening is slightly more accurate than sequential screening, but results take longer.
If screening indicates a risk of a birth defect, the doctor may recommend diagnostic testing.
Second-trimester genetic screening: Monitoring fetal health
Additional screening during the second trimester may include:
AFP (alpha-fetoprotein) test: This screens for neural tube defects and may be performed after cell-free fetal DNA testing.
Maternal serum quad screen: This blood test assesses the risk of Down syndrome, trisomy 18, and neural tube or brain conditions, usually between 15 and 21 weeks.
Integrated screening (second part): If the first part was completed during the first trimester, the second blood test is performed at 16-18 weeks.
Ultrasound: Usually performed at 20 weeks, it uses sound waves to create images of the fetus and check for birth defects such as cleft lip and palate, heart conditions, and kidney conditions.
Diagnostic testing: Amniocentesis and chorionic villus sampling
Amniocentesis and chorionic villus sampling (CVS) are common diagnostic tests used to determine whether a fetus has a birth defect or inherited condition. Both are more than 99% accurate.
Chorionic villus sampling (CVS): A small sample of chorionic villus tissue is taken from the uterus using a thin needle or tube, usually between 10 and 13 weeks. It may cause mild cramping, bleeding, or infection.
Amniocentesis: A doctor passes a long, thin needle through the abdomen into the amniotic sac and removes a small amount of fluid for analysis. It is usually performed between 15 and 20 weeks and may cause mild bleeding, cramping, or infection.
Although these tests carry some risk, they provide the most accurate diagnostic information. The doctor will determine whether they are appropriate based on screening results and the patient's circumstances.
Conclusion
Genetic testing can provide expectant parents with deeper insight and support informed pregnancy-care decisions. Choosing appropriate screening at different stages can clarify the risk of inherited conditions and support maternal and fetal care. Before any test, discuss its benefits, limitations, risks, and possible results with a doctor.
Guide | From Preconception to the Second Trimester: Genetic Screening and Diagnostic Testing
Guide | From Preconception to the Second Trimester: Genetic Screening and Diagnostic Testing
As technology advances, genetic testing has become an important tool in pregnancy care. Before pregnancy and during the first and second trimesters, it can give prospective parents important information about their baby's health and support informed healthcare decisions. This article introduces genetic testing options at each stage of pregnancy.
Preconception genetic screening: Understanding carrier status
Carrier screening is one of the most common tests before pregnancy. A person who carries a gene for an inherited condition without having symptoms is called a carrier. Carrier screening can determine whether you and your partner carry certain variants and assess the chance of passing them to a child.
Testing can be done before or early in pregnancy, but testing before pregnancy provides more options. Doctors usually use a blood or saliva sample to screen for common inherited conditions, including:
Cystic fibrosis
Fragile X syndrome
Sickle cell anemia
Tay-Sachs disease
Spinal muscular atrophy
Some populations, including non-Hispanic White people, Eastern European Jewish people, and people of African, Mediterranean, or Southeast Asian ancestry, may be more likely to carry certain conditions. Preconception genetic screening may therefore be recommended for higher-risk groups.
First-trimester genetic screening: Assessing the baby's health risks
Early in pregnancy, a doctor may recommend genetic screening for potential health concerns. Common first-trimester options include:
Cell-free fetal DNA testing: This test analyzes fetal DNA in the pregnant woman's blood to screen for Down syndrome, trisomy 18, trisomy 13, and sex chromosome conditions. It can be used from 10 weeks of pregnancy.
Sequential screening: Ultrasound and blood tests are combined to assess the risk of Down syndrome, trisomy 18, and neural tube or brain conditions. It is usually performed between 10 and 13 weeks.
Integrated screening: This combines ultrasound and blood tests to assess the risk of Down syndrome, trisomy 18, and neural tube or brain conditions. The first part is usually performed at 12 weeks and the second during the second trimester. Integrated screening is slightly more accurate than sequential screening, but results take longer.
If screening indicates a risk of a birth defect, the doctor may recommend diagnostic testing.
Second-trimester genetic screening: Monitoring fetal health
Additional screening during the second trimester may include:
AFP (alpha-fetoprotein) test: This screens for neural tube defects and may be performed after cell-free fetal DNA testing.
Maternal serum quad screen: This blood test assesses the risk of Down syndrome, trisomy 18, and neural tube or brain conditions, usually between 15 and 21 weeks.
Integrated screening (second part): If the first part was completed during the first trimester, the second blood test is performed at 16-18 weeks.
Ultrasound: Usually performed at 20 weeks, it uses sound waves to create images of the fetus and check for birth defects such as cleft lip and palate, heart conditions, and kidney conditions.
Diagnostic testing: Amniocentesis and chorionic villus sampling
Amniocentesis and chorionic villus sampling (CVS) are common diagnostic tests used to determine whether a fetus has a birth defect or inherited condition. Both are more than 99% accurate.
Chorionic villus sampling (CVS): A small sample of chorionic villus tissue is taken from the uterus using a thin needle or tube, usually between 10 and 13 weeks. It may cause mild cramping, bleeding, or infection.
Amniocentesis: A doctor passes a long, thin needle through the abdomen into the amniotic sac and removes a small amount of fluid for analysis. It is usually performed between 15 and 20 weeks and may cause mild bleeding, cramping, or infection.
Although these tests carry some risk, they provide the most accurate diagnostic information. The doctor will determine whether they are appropriate based on screening results and the patient's circumstances.
Conclusion
Genetic testing can provide expectant parents with deeper insight and support informed pregnancy-care decisions. Choosing appropriate screening at different stages can clarify the risk of inherited conditions and support maternal and fetal care. Before any test, discuss its benefits, limitations, risks, and possible results with a doctor.
Story source:
Compiled from online sources